Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Severe Uncontrolled Asthma (DIRECTION)
NCT03927157Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Annual Asthma Exacerbation Rate at 52 weeks. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03927157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927157.